Dashboard
Manage Tickers

GTHX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

breaking-down-g1-therapeutics-5-analysts-share-their-views
Breaking Down G1 Therapeutics: 5 Analysts ...
04/12/2024 14:02:12

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
04/12/2024 10:00:06

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/08/2024 12:09:45

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
02/28/2024 17:31:10

forecasting-the-future-5-analyst-projections-for-g1-therapeutics
Forecasting The Future: 5 Analyst Projecti...
02/28/2024 17:01:01

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
02/28/2024 16:45:12

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

g1-therapeutics-ended-2023-with-cash-cash-equivalents-and-marketable-securities-of-822m-with-cash-runway-expected-into-2025
G1 Therapeutics Ended 2023 With Cash, Cash...
02/28/2024 11:39:02

g1-therapeutics-q4-eps-021-beats-028-estimate-sales-1487m-beat-1308m-estimate
G1 Therapeutics Q4 EPS $(0.21) Beats $(0.2...
02/28/2024 11:38:09

G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.2...

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

why-is-breast-cancer-focused-g1-therapeutics-stock-trading-lower-today
Why Is Breast Cancer-Focused G1 Therapeuti...
02/13/2024 18:24:45

Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Upd...

why-ipg-photonics-shares-are-trading-lower-by-around-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why IPG Photonics Shares Are Trading Lower...
02/13/2024 18:13:36

Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed four...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
02/13/2024 17:31:12

why-zoominfo-technologies-shares-are-trading-higher-by-around-25-here-are-20-stocks-moving-premarket
Why ZoomInfo Technologies Shares Are Tradi...
02/13/2024 13:36:44

Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-...

wedbush-maintains-outperform-on-g1-therapeutics-lowers-price-target-to-4
Wedbush Maintains Outperform on G1 Therape...
02/13/2024 13:27:11

Wedbush analyst David Nierengarten maintains G1 Therapeutics (NASDAQ:GTHX) with a Outperform and lowers the price target fro...

zoominfo-technologies-to-rally-around-50-here-are-10-top-analyst-forecasts-for-tuesday
ZoomInfo Technologies To Rally Around 50%?...
02/13/2024 13:08:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/13/2024 13:06:00

needham-maintains-buy-on-g1-therapeutics-lowers-price-target-to-12
Needham Maintains Buy on G1 Therapeutics, ...
02/13/2024 12:03:00

Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $14 to $12.

arista-networks-reports-q4-results-joins-teradata-lattice-semiconductor-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Arista Networks Reports Q4 Results, Joins ...
02/13/2024 10:29:09

U.S. stock futures were lower this morning, with the Nasdaq futures trading lower by around 100 points on Tuesday.

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
02/12/2024 21:30:59

g1-therapeutics-continues-phase-3-trial-of-trilaciclib-in-metastatic-triple-negative-breast-cancer-following-interim-analysis-by-independent-data-monitoring-committee
G1 Therapeutics Continues Phase 3 Trial Of...
02/12/2024 21:06:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION